Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab

Lung cancer; wooden puzzle on dark surface
Questions about Lumakras in KRAS G12C-mutated lung cancer with co-mutations may be answered in Phase III • Source: Alamy

More from ASCO

More from Conferences